$BRKR

Munch Mark sold $110K of BRKR

Munch Mark (EXEC VP&PRES BRUKER NANO INC.) sold 2,000 shares of BRUKER CORP (BRKR) at $54.76 ($0.11M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Munch Mark
Published Jun 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
high confidence
Mentioned
$BRKR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

This is a primary-source disclosure of an insider sale, but the presence of a pre-arranged 10b5-1 plan typically makes it lower-signal for fundamentals.

02

Market read

Traders may note the disclosed sale size and timing, but it is unlikely to drive a material repricing absent other company-specific news.

03

What to watch

The article does not disclose motivations, remaining plan schedule, or whether other insiders sold around the same time, limiting inference.

Relevance 3/10Novelty 2/10Timing: SEC Form 4 filed 2026-06-16, covering a sale executed 2026-06-15.

Background

The filing is an SEC Form 4 insider transaction for Bruker Corp, reported by an executive officer and executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$BRKRNeutralHigh confidence
Context

Form 4 shows Bruker insider Munch Mark sold 2,000 shares at $54.76 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is typically absorbed as non-informational 10b5-1 selling.

Evidence & confidence

The transaction is explicitly coded as an open-market sale and states a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive value versus discretionary sales.

Market effects

No sector-level implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation or liquidity management, so traders may still watch for follow-on selling patterns.

Key entities

  • BRUKER CORP

    Subject of the Form 4 insider transaction disclosure.

  • Munch Mark

    Executive VP and President of Bruker Nano Inc., reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.

$BRKRMed

Why Bruker (BRKR) Stock Is Falling Today

Bruker (BRKR) shares fell 6.3% after UBS initiated coverage with a Neutral rating and a $65 price target, citing AI-related tailwinds and ongoing headwinds. The company's stock has been volatile, with a 17.7% drop last month due to missed revenue expectations and lowered guidance. BRKR is up 13.1% YTD but trades 15.5% below its 52-week high.

$BRKRHighAI 8/10

Bruker (BRKR) Wagers On Fusion Energy While Wall Street Waits

Bruker (BRKR) announced a supply collaboration with Luvata to scale up production of RRP superconductors for fusion energy. BEST unit revenue grew 11.9% YoY to $74.2M in Q2, with non-GAAP EPS at $0.49. GAAP results showed a $65.3M loss due to goodwill impairments. Bruker maintains full-year non-GAAP EPS growth target of 15-17%.

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.